Akansha Ashvani Sehgal1,2, Yuguo Li1,2, Bachchu Lal3, Nirbhay N Yadav1,2, Xiang Xu1,2, Jiadi Xu1,2, John Laterra3, Peter C M van Zijl1,2. 1. Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland. 3. Department of Neurology, Oncology, and Neuroscience, The Johns Hopkins Medicine, and The Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.
Abstract
PURPOSE: 3-O-Methyl-D-glucose (3-OMG) is a nonmetabolizable structural analog of glucose that offers potential to be used as a CEST-contrast agent for tumor detection. Here, we explore it for CEST-detection of malignant brain tumors and compare it with D-glucose. METHODS: Glioma xenografts of a U87-MG cell line were implanted in five mice. Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg). RESULTS: Tumor regions showed higher enhancement as compared to contralateral brain. The CEST contrast enhancement in the tumor region ranged from 2.5-5.0%, while it was 1.5-3.5% in contralateral brain. Previous D-glucose studies of the same tumor model showed an enhancement of 1.5-3.0% and 0.5-1.5% in tumor and contralateral brain, respectively. The signal gradually stabilized to a value that persisted for the length of the scan. CONCLUSIONS: 3-OMG shows a CEST contrast enhancement that is approximately twice as much as that of D-glucose for a similar tumor line. In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors.
PURPOSE:3-O-Methyl-D-glucose (3-OMG) is a nonmetabolizable structural analog of glucose that offers potential to be used as a CEST-contrast agent for tumor detection. Here, we explore it for CEST-detection of malignant brain tumors and compare it with D-glucose. METHODS:Glioma xenografts of a U87-MG cell line were implanted in five mice. Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg). RESULTS:Tumor regions showed higher enhancement as compared to contralateral brain. The CEST contrast enhancement in the tumor region ranged from 2.5-5.0%, while it was 1.5-3.5% in contralateral brain. Previous D-glucose studies of the same tumor model showed an enhancement of 1.5-3.0% and 0.5-1.5% in tumor and contralateral brain, respectively. The signal gradually stabilized to a value that persisted for the length of the scan. CONCLUSIONS:3-OMG shows a CEST contrast enhancement that is approximately twice as much as that of D-glucose for a similar tumor line. In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors.
Authors: D J Brooks; R P Beaney; A A Lammertsma; S Herold; D R Turton; S K Luthra; R S Frackowiak; D G Thomas; J Marshall; T Jones Journal: J Cereb Blood Flow Metab Date: 1986-04 Impact factor: 6.200
Authors: Xiang Xu; Akansha Ashvani Sehgal; Nirbhay N Yadav; John Laterra; Lindsay Blair; Jaishri Blakeley; Anina Seidemo; Jennifer M Coughlin; Martin G Pomper; Linda Knutsson; Peter C M van Zijl Journal: Magn Reson Med Date: 2019-12-24 Impact factor: 4.668
Authors: Zheng Han; Chuheng Chen; Xiang Xu; Renyuan Bai; Verena Staedtke; Jianpan Huang; Kannie W Y Chan; Jiadi Xu; David O Kamson; Zhibo Wen; Linda Knutsson; Peter C M van Zijl; Guanshu Liu Journal: NMR Biomed Date: 2021-11-15 Impact factor: 4.044
Authors: Ben R Dickie; Tao Jin; Ping Wang; Rainer Hinz; William Harris; Hervé Boutin; Geoff Jm Parker; Laura M Parkes; Julian C Matthews Journal: J Cereb Blood Flow Metab Date: 2022-06-23 Impact factor: 6.960
Authors: Qi Qi; Matthew S Fox; Heeseung Lim; Robert Bartha; Timothy J Scholl; Lisa Hoffman; Ting-Yim Lee; Jonathan D Thiessen Journal: Mol Imaging Biol Date: 2021-02-03 Impact factor: 3.488